Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)

Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

Restoring metabolic balance
to treat NASH and other
serious metabolic diseases

Minimally invasive
heart valve
devices

Preventing axonal degeneration
in patients with
neurological diseases

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Innovative micro-RNA-
based therapies –
IPO Feb 2017 (NASDAQ: MGEN)

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

Re-dosable, titratable genetic
medicines with drug-like properties
for patients with genetic diseases

Novel bicyclic peptides (bicycles)
and bicycle drug conjugates
for cancer

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)

First-in-class
RNA therapies
for severe genetic diseases

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

Stimulating the innate and
adaptive immune system in a
novel approach to treat cancer

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Creating breakthrough
therapies for neurological
and psychiatric conditions

Highly-potent, targeted, and
combinable immuno-oncology
therapeutics

Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016

Small molecule
drug design
using statistical modeling

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Novel MetAP2 therapeutics to transform
complex metabolic disorders –
IPO June 2014 (NASDAQ: ZFGN)

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Novel therapeutics
targeting
diseases of aging

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

Breakthrough computer-aided
drug design
for transformative medicines

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

Pioneering targeted
therapies for serious
muscle diseases

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

Targeting RNA-modifying
proteins for novel
precision cancer therapies

New class of
regulated cell and
gene therapies

Discovering and developing
novel integrin antagonists for
serious fibrotic diseases

Bispecific antibodies
to improve the treatment
of serious diseases

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

Enhancing synaptic integrity
for treatment of
neurologic disorders

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Designing Synthetic Biotic
living medicines to treat disease
(NASDAQ: SYBX)

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)

Unlocking nature’s regulatory
mechanisms to fuel the
discovery of new medicines

Cell and gene therapies
for rare diseases
IPO Jun 2018 (NASDAQ: AVRO)

Advancing targeted protein
degradation to target previously
“undruggable” disease pathways

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Precision therapeutics for
genetically-defined age-related
macular degeneration and rare diseases

Universal cell-based
cancer immunotherapy
IPO Mar 2018 (NASDAQ: UMRX)

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Discovering new medicines
for severe
neurodegenerative diseases